Alain Balland

Director CMC strategy at Boeheringer-Ingelheim

Biberach an der Riß, Baden-Württemberg, Germany

About

- Protein chemist with extensive experience in biopharmaceutical development and protein characterization. - Responsible for reaching a "well characterized" status for recombinant proteins in clinical development, with special emphasis on critical quality attributes (cQA) assessment and quality by design (QbD). - Provide scientific leadership and coordinate departmental activities at different stages of development, manufacturability assessment, IND, phase I-III clinical trials, BLA, post-approval commitments. - Provide CMC expertize to support regulatory filings of biopharmaceuticals and succesful interactions with health authorities. - Responsible for driving cross-functional CMC development strategies for key drug development projects, including early to late stage and major post-launch improvement program Specialties: Analytical development of therapeutic proteins. CMC strategy for successful regulatory filings of biopharmaceuticals

Experience

  • Director CMC strategy at Boeheringer-Ingelheim
    Mar 2015 - Present · 11 yrs 5 mos

  • Amgen ()
    • Scientific Director
      2003 - 2014 · 11 yrs

    • Principal Scientist
      2002 - 2003 · 1 yr

  • Immunex ()
    • Principal Scientist
      1998 - 2002 · 4 yrs

    • Senior Scientist
      1994 - 1998 · 4 yrs

    • Staff Scientist
      1991 - 1994 · 3 yrs